4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring

Evolution of Cancer Survivorship: The Landmark IOM Framework

With advances in early detection, multimodal surgery, precision radiotherapy, and targeted systemic therapies, the population of breast cancer survivors has expanded dramatically, representing the largest single group of cancer survivors in the United States. However, the completion of acute active therapy often marks a vulnerable juncture in cancer care. In 2005, the Institute of Medicine (IOM, now the National Academy of Medicine) published its groundbreaking report, From Cancer Patient to Cancer Survivor: Lost in Transition. This landmark publication illuminated the profound clinical gap between acute cancer therapy and post-treatment survivorship, describing cancer patients as surviving active treatment only to find themselves lost in a fragmented healthcare system that fails to address their ongoing physical, psychological, and informational needs.

The Four Core Components of Survivorship Care

The IOM framework defined cancer survivorship as a distinct phase of the cancer care continuum beginning at the completion of primary treatment and continuing throughout the remainder of life. The report articulated four foundational pillars essential to high-quality survivorship care:

1. Prevention of Recurrent and New Malignancies and Late Effects: Implementing proactive lifestyle modifications, chemoprevention strategies, and behavioral interventions to prevent primary disease recurrence, contralateral second primary breast cancers, secondary treatment-induced malignancies, and chronic cardiopulmonary or musculoskeletal toxicities.
2. Surveillance for Cancer Spread, Recurrence, or Secondary Malignancies: Conducting systematic, evidence-based clinical history, physical assessment, and targeted screening imaging to detect locoregional recurrences or secondary neoplasms at an early, potentially treatable stage, while monitoring for insidious late treatment-related toxicities.
3. Intervention for the Physical and Psychosocial Consequences of Cancer and Its Treatment: Identifying and managing long-term and late treatment toxicities, including lymphedema, sexual dysfunction, genitourinary syndrome of menopause (GSM), musculoskeletal pain, aromatase inhibitor-induced arthralgias, cancer-related fatigue, chemotherapy-induced peripheral neuropathy (CIPN), premature ovarian failure, osteoporosis, cognitive dysfunction ('chemobrain'), body image disturbance, and fear of cancer recurrence.
4. Coordination Between Oncology Specialists and Primary Care Providers: Establishing formalized communication and shared-care pathways between oncology multidisciplinary teams and primary care clinicians to ensure that ongoing non-oncology preventive care (such as lipid management, cardiovascular screening, diabetes care, and non-breast cancer age-appropriate cancer screenings) is delivered without duplication or omission.

---

Components and Delivery of the Survivorship Care Plan (SCP)

To translate the IOM recommendations into clinical practice, national oncology organizations—including the American Society of Clinical Oncology (ASCO), the Commission on Cancer (CoC), and the National Comprehensive Cancer Network (NCCN)—established standardized criteria for the Survivorship Care Plan (SCP). The Commission on Cancer required SCPs from 2015 until its 2020 standards replaced that mandate with a requirement for a survivorship program, but treatment summaries and follow-up care plans remain best practice. The SCP represents a personalized, comprehensive clinical document prepared by the oncology team and delivered to both the patient and their designated primary care provider upon completion of acute primary curative-intent therapy.

A complete SCP comprises two interdependent sections: the Treatment Summary and the Follow-Up Care Plan.

The Treatment Summary

The Treatment Summary documents all diagnostic, pathologic, and therapeutic parameters of the patient's cancer journey. Accurate documentation is vital for subsequent risk stratification and long-term toxicity surveillance:

• Diagnostic and Pathologic Staging: Date of diagnosis, laterality, histologic subtype (e.g., invasive ductal carcinoma, invasive lobular carcinoma), histologic tumor grade, and American Joint Committee on Cancer (AJCC) anatomic and prognostic TNM stage.
• Receptor Biomarker Status: Estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 protein expression by immunohistochemistry (IHC) and gene amplification by in situ hybridization (FISH), and proliferation index (Ki-67).
• Genomic Recurrence Assays: Recurrence Score results (e.g., Oncotype DX, MammaPrint, Prosigna) if performed to guide systemic therapy decisions.
• Surgical Interventions: Nature and date of primary breast surgery (breast-conserving lumpectomy vs. total mastectomy, nipple-sparing, skin-sparing), final surgical margin status (e.g., no ink on tumor for invasive carcinoma; negative margins $\ge 2\text{ mm}$ for ductal carcinoma in situ), axillary staging technique (sentinel lymph node biopsy [SLNB] vs. axillary lymph node dissection [ALND]), total number of lymph nodes resected, and number of positive lymph nodes.
• Reconstructive Details: Immediate vs. delayed reconstruction, type of reconstruction (prosthetic tissue expander/silicone implant vs. autologous DIEP, TRAM, or latissimus dorsi flap).
• Radiation Therapy (RT): Modality (3D conformal RT, intensity-modulated RT [IMRT], hypofractionated whole-breast irradiation, accelerated partial breast irradiation [APBI]), total radiation dose delivered (in Gray [Gy]), fractionation schedule, specific anatomical treatment fields (whole breast, chest wall, regional nodal irradiation including supraclavicular, axillary, and internal mammary basins), and tumor bed boost dose.
• Systemic Chemotherapy: Specific regimens and agents administered (e.g., doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin), number of cycles completed, start and completion dates, cumulative anthracycline exposure (calculated in $\text{mg/m}^2$ of doxorubicin or epirubicin equivalents for lifetime cardiotoxicity tracking), and cumulative taxane exposure.
• Targeted Biologic Therapies: Monoclonal antibodies (trastuzumab, pertuzumab) or antibody-drug conjugates (ado-trastuzumab emtansine [T-DM1]), duration of therapy, and end dates.
• Endocrine / Hormonal Therapy: Prescribed endocrine agent (tamoxifen, anastrozole, letrozole, exemestane), use of concurrent ovarian function suppression (goserelin, leuprolide), planned duration (5 vs. 10 years), and anticipated completion date.
• Adverse Reactions and Acute Toxicities: Severe treatment toxicities experienced during active therapy (e.g., grade 3/4 neutropenic fever, taxane hypersensitivity reaction, symptomatic cardiomyopathy, thromboembolic event).

The Follow-Up Care Plan

The Follow-Up Care Plan provides a forward-looking clinical roadmap detailing ongoing surveillance testing, chronic symptom management, health promotion strategies, and referral networks:

• Clinical Surveillance Schedule: Explicit timetable specifying the frequency of clinical history and physical assessments and designating the responsible provider (medical oncologist, surgical oncologist, radiation oncologist, or primary care physician).
• Surveillance Imaging Schedule: Prescribed intervals for follow-up diagnostic mammography, tomosynthesis, or supplemental screening MRI for eligible high-risk patients.
• Late and Long-Term Toxicity Monitoring: Organ-specific surveillance instructions based on prior treatments, including baseline and serial bone mineral density (DEXA) scans every 1 to 2 years for patients on aromatase inhibitors or ovarian suppression; periodic echocardiograms or multigated acquisition (MUGA) scans for patients with significant anthracycline or trastuzumab exposure; and clinical screening for lymphedema, CIPN, and cardiotoxicity.
• Secondary Prevention and Wellness Guidance: Evidence-based recommendations for aerobic and resistance exercise, dietary optimization, weight maintenance, tobacco cessation, and alcohol reduction.
• Psychosocial and Community Resources: Contact information for specialized oncology social work, psychological counseling, peer support networks, sexual health counselors, and financial navigators.
• Genetic Counseling Recommendations: Formal notation regarding whether hereditary genetic testing was performed, results obtained, or whether subsequent genetic referral is indicated based on personal or emerging family history.

---

ASCO and NCCN Evidence-Based Post-Treatment Surveillance Guidelines

Clinical follow-up for breast cancer survivors treated with curative intent must balance early detection of treatable locoregional recurrences against the risks of overtreatment, radiation exposure, and procedural complications from unguided testing. ASCO and the National Comprehensive Cancer Network (NCCN) publish closely matching post-treatment surveillance standards; the schedule below is ASCO's, and NCCN phrases it as a visit 1 to 4 times per year for 5 years, then annually.

History and Physical Examination

A thorough, focused history and physical examination remains the most effective clinical modality for detecting locoregional recurrences and assessing treatment toxicities:

• Years 1 through 3: Clinical examination every 3 to 6 months.
• Years 4 through 5: Clinical examination every 6 to 12 months.
• Year 6 and Beyond: Annual clinical examination for life.

The clinical physical examination must be performed systematically and include:

1. Careful Inspection and Palpation of the Preserved Breast and/or Chest Wall: Inspecting for new localized skin erythema, cutaneous thickening, edema, dimpling, retraction, ulceration, or palpable dermal nodules along mastectomy scars or lumpectomy sites.
2. Assessment of Regional Lymph Node Basins: Bilateral palpation of the axillary fossa, infraclavicular fossa, supraclavicular fossa, and cervical chains. Palpable metastatic lymph nodes are typically firm to stony-hard, non-tender, and matted or fixed.
3. Evaluation of the Contralateral Breast: Complete clinical breast examination using a standardized vertical-strip technique.
4. Systemic Review of Systems: Specifically querying constitutional symptoms (unintentional weight loss, night sweats), skeletal symptoms (focal persistent bone pain), pulmonary symptoms (chronic dry cough, progressive exertional dyspnea), abdominal symptoms (right upper quadrant pain, early satiety), and neurological changes (new progressive headaches, seizures, focal weakness).

Surveillance Breast Imaging Protocols

• Breast-Conserving Surgery (Lumpectomy): Patients who underwent breast-conserving surgery followed by whole-breast irradiation must receive their first post-treatment diagnostic mammogram (bilateral, including dedicated magnification or spot compression views of the surgical bed) 6 to 12 months after the completion of radiation therapy. Subsequent diagnostic or screening mammograms are performed annually thereafter. Radiation-induced tissue edema, parenchymal sclerosis, and fat necrosis can simulate or obscure malignancy; establishing a new post-radiation baseline mammogram is critical to distinguish stable post-surgical scar tissue from recurrent neoplasia.
• Unilateral Total Mastectomy: Patients who underwent unilateral mastectomy require annual screening mammography of the preserved contralateral breast. Mammographic evaluation of the reconstructed breast or mastectomy flap is not indicated in the absence of suspicious clinical findings.
• Bilateral Total Mastectomy: Routine surveillance mammography or other routine screening imaging is not recommended for patients who have undergone bilateral total mastectomy (with or without alloplastic implant or autologous flap reconstruction). The amount of residual breast parenchyma following complete mastectomy is negligible. Surveillance consists entirely of regular clinical history and physical examination of the chest wall, skin flaps, and regional nodal stations.
• Supplemental Screening Breast MRI: Routine surveillance breast MRI is not recommended for average-risk survivors. However, annual supplemental contrast-enhanced breast MRI in conjunction with annual mammography is recommended for survivors at persistently high risk for a secondary primary breast cancer, including patients with documented pathogenic germline variants (e.g., BRCA1, BRCA2, PALB2, TP53, PTEN), patients with a calculated lifetime risk of $\ge 20\%$, or those who received therapeutic mantle radiation to the chest prior to age 30.

---

Subsequent (Second) Malignancies

Surveillance also watches for new cancers, not only recurrence:

• Contralateral breast cancer: roughly 0.3% to 0.5% per year in unselected survivors, higher in BRCA1/2 carriers and young patients; endocrine therapy lowers it by about half in ER-positive disease.
• Therapy-related myeloid neoplasms (MDS/AML): linked to anthracyclines, alkylators, and radiation, typically within 1 to 7 years; report new cytopenias, easy bruising, or recurrent infections.
• Radiation-associated angiosarcoma and other sarcomas: rare, arising in the irradiated field years later; any new purple skin lesion on the treated breast needs biopsy.
• Endometrial cancer and uterine sarcoma with tamoxifen: postmenopausal bleeding needs prompt gynecologic evaluation.
• Lung cancer after radiation, especially in smokers, plus the age-appropriate cancers that primary care screens for.

When a Patient Declines Recommended Treatment

The outline names declination of treatment under surveillance. An informed adult may refuse surgery, radiation, endocrine therapy, or chemotherapy. The nurse confirms that the refusal is informed (the patient understands the likely consequences in plain numbers), explores the reasons (fear, cost, transportation, side effects, cultural or religious values, mistrust), offers alternatives such as a different endocrine agent or a shorter radiation schedule, and documents an informed refusal. Declining one therapy does not end the relationship: the patient keeps a surveillance plan that is often more intensive (for example, clinical examination and imaging of an untreated primary every 3 to 6 months), is re-offered treatment at later visits, and continues to receive symptom management and supportive care. Respect the decision without abandoning the patient.

---

The Choosing Wisely Campaign: Overtreatment and Unwarranted Diagnostic Staging

A critical domain of oncology nursing and survivorship practice is guiding patients through the misconceptions surrounding post-treatment surveillance testing. Patients frequently experience acute scan-related anxiety ('scanxiety') and assume that frequent full-body scans and blood tests offer the best reassurance against recurrence.

The Evidence Against Routine Systemic Staging and Tumor Markers

The American Society of Clinical Oncology, in partnership with the American Board of Internal Medicine (ABIM) Foundation's Choosing Wisely campaign, issued explicit clinical guidance: Do not perform routine systemic surveillance imaging (such as PET/CT, diagnostic chest/abdomen/pelvis CT, or radionuclide bone scans) or routine serum tumor markers (such as CA 15-3, CA 27-29, or CEA) in asymptomatic patients who have completed curative-intent therapy for early-stage breast cancer.

---

Clinical Signs and Symptoms of Recurrence Warranting Immediate Workup

While routine indiscriminate testing is contraindicated, any new, persistent, or progressive clinical finding requires immediate, targeted diagnostic investigation. Breast care nurses educate patients to contact their oncology team promptly if specific 'red flag' symptoms develop, rather than waiting for scheduled follow-up visits.

Skeletal Metastases (Bone)

The skeleton represents the most common site of distant hematogenous metastasis in breast cancer, occurring in approximately 60% to 70% of patients with metastatic recurrence, particularly those with hormone receptor-positive disease.

• Clinical Presentation: Persistent, progressive, localized bone pain—most frequently involving the thoracic or lumbar spine, ribs, pelvis, or proximal femur. The pain is typically dull, aching, deep, constant, and characteristically worsens at night or during recumbency and is not relieved by rest or standard over-the-counter analgesics.
• Oncologic Emergency — Spinal Cord Compression: Metastatic lesions in the vertebral bodies can collapse or extend epidurally into the spinal canal. Patients presenting with localized mid-back pain accompanied by progressive bilateral lower-extremity motor weakness, lower-extremity sensory loss (numbness, paresthesias in a dermatomal distribution), gait ataxia, or acute bowel or urinary incontinence/retention require emergency MRI of the entire spine and immediate administration of intravenous dexamethasone followed by urgent radiation oncology or neurosurgical intervention to prevent permanent paraplegia.
• Pathologic Fracture: Sudden onset of severe, acute pain upon minimal physical movement or weight-bearing indicates osteolytic cortical destruction.

Pulmonary and Pleural Metastases

Pulmonary parenchyma and pleura represent the second most common site of visceral dissemination.

• Clinical Presentation: A new, unexplained, non-productive dry cough persisting for longer than two to three weeks, progressive exertional dyspnea, pleuritic chest pain that sharpens upon deep inspiration, or hemoptysis.
• Diagnostic Approach: Physical examination revealing absent or diminished breath sounds at the lung bases suggests malignant pleural effusion. Workup includes diagnostic contrast-enhanced chest CT and diagnostic thoracentesis with pleural fluid cytology.

Hepatic Metastases (Liver)

Hepatic recurrence is common in HER2-positive and aggressive triple-negative subtypes, but can occur across all molecular classes.

• Clinical Presentation: Persistent right upper quadrant abdominal fullness, dull aching pain, unexplained anorexia, early satiety, severe nausea, profound unexplained fatigue, progressive abdominal distention from malignant ascites, and scleral icterus or cutaneous jaundice.
• Diagnostic Approach: Elevation of serum alkaline phosphatase, gamma-glutamyl transferase (GGT), and total bilirubin on laboratory evaluation warrants immediate multiphase contrast-enhanced abdominal CT or MRI, followed by image-guided core biopsy to confirm histopathology and re-evaluate receptor biomarkers.

Central Nervous System (CNS) Metastases

Brain and leptomeningeal metastases occur in 15% to 30% of patients with metastatic breast cancer, with the highest incidence observed in HER2-positive and triple-negative breast cancer (TNBC).

• Clinical Presentation: A new, severe, progressive headache that characteristically awakens the patient from sleep in the early morning, worsens with coughing or the Valsalva maneuver, and is accompanied by projectile vomiting without prior nausea (classic signs of elevated intracranial pressure). Additional manifestations include focal neurological deficits (hemiparesis, facial droop, dysphasia), visual changes (diplopia, visual field cuts, papilledema), new-onset seizures in an adult without a history of epilepsy, cognitive slowing, confusion, or personality changes.
• Diagnostic Approach: Contrast-enhanced multiplanar brain MRI (preferred over non-contrast CT due to superior sensitivity for small parenchymal or posterior fossa lesions).